About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Thursday, May 14th, 2015

The QualityStocks
Daily Stock List



Innovative Marketing, Zacks, TopPennyStockMovers, BabyBulls, and SmallCapVoice reported on ULURU, Inc. (ULUR), and today we report on the Company as well, here at the QualityStocks Daily Newsletter.

ULURU, Inc. is a specialty pharmaceutical company that is concentrating on the development of a portfolio of wound management and oral care products. This is to provide patients and consumers improved clinical outcomes through controlled delivery using the Company’s innovative Nanoflex® Aggregate technology and OraDisc™ transmucosal delivery system. ULURU has its headquarters in Addison, Texas.

The Company’s business strategy is to develop and commercialize a customer-focused portfolio of ground-breaking wound care products to treat the different phases of wound healing. Furthermore, ULURU’s strategy involves developing the oral-transmucosal technology and generating revenues via numerous licensing agreements.

ULURU’s products include Altrazeal®. It developed and commercializes Altrazeal® - a transforming powder dressing with proprietary Nanoflex® technology, for the management of exuding wounds. Altrazeal® is a scientifically engineered advanced wound dressing designed to incorporate the desired features and benefits of the ideal wound dressing.

Altrazeal® has demonstrated potential clinical and economic advantages in several chronic and acute wounds. These include diabetic foot ulcers, venous leg ulcers, and geriatric wounds. Altrazeal® has now been launched onto the German market. ULURU was also advised by the Chinese patent office that the patent covering Altrazeal® has been issued. This further expands the wide-ranging global patent protection ULURU has achieved for Altrazeal®.
ULURU’s products also include Aphthasol®. It contains 5% amlexanox in an adhesive oral paste. Aphthasol® is Food and Drug Administration (FDA) approved and indicated for the treatment of aphthous ulcers in people with normal immune systems.

ULURU also has its OraDisc™A. It developed OraDisc™ A, a novel mucoadhesive, water-erodible disc incorporating 2mg of amlexanox, for the treatment and prevention of aphthous ulcers. Its OraDisc™ B is a mucoadhesive erodible disc containing 15 mg of benzocaine, which has undergone development for the treatment of oral pain.

ULURU also developed a unique, patented delivery strip for whitening teeth which completely erodes (OraDisc™ W- Erodible Whitening Strip for Teeth). Its proprietary tooth whitening product consists of a laminated bilayer strip that uses the OraDisc™ technology.

Today, ULURU announced that it will be acquiring the 75 percent ownership of Altrazeal Trading GmbH not now owned by the Company.  It was granted the option pursuant to a Shareholders Agreement dated January 11, 2012, to acquire the remaining ownership for a predetermined valuation. Altrazeal Trading GmbH was formed to commercialize Altrazeal, ULURU’s proprietary wound care product, in Europe, the Middle East, and Australia/New Zealand.

ULURU, Inc. (ULUR), closed Thursday's trading session at $0.55, up 41.03%, on 224,279 volume with 81 trades. The average volume for the last 60 days is 25,833 and the stock's 52-week low/high is $0.25/$1.60.

CannaVest Corp. (CANV)

Wall Street Resources reported earlier on CannaVest Corp. (CANV), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

CannaVest Corp. engages in developing, producing, marketing, and selling end consumer products to the nutraceutical industry containing the hemp plant extract, Cannabidiol (CBD). CBD undergoes refining into the Company’s own PlusCBD Oil™ brand. In addition, CannaVest engages in reselling to third parties raw product acquired by it pursuant to its supply relationships in Europe. CannaVest subsidiaries include US Hemp Oil, LLC and CannaVest Laboratories, LLC. CannaVest is headquartered in Las Vegas, Nevada.

The Company’s intention is to diversify its business primarily into four operating segments. These include securing and supplying raw hemp product for sale to third parties; developing, producing, marketing, and selling consumer products to the nutraceutical industry containing CBD; establishing and helping others to establish farming operations focused on the growth of industrial hemp; and investing in companies in its industry.

US Hemp Oil, LLC provides seed procurement, cultivation, processing, and production consultation; and equipment to support U.S. farmers, researchers, and businesses to cultivate and process industrial hemp in the U.S.  US Hemp Oil plans to build seed-processing mills and bring hemp based products to market.

CannaVest Laboratories facilitates pioneering research and develops nutraceutical and food products containing cannabidiol (CBD) oil. CannaVest Laboratories is the developer and manufacturer of CannaVest’s own award winning CBD Simple™.

CannaVest Laboratories is equipped with state-of-the-art, high-performance equipment and distillation tools to produce award winning CBD Simple™, and PlusCBD™ Oil. CannaVest has secured the exclusive production supply of around 2,500 acres of European industrial hemp farmland, through the 2018 harvest. It has an option to extend the acreage or length of the commitment.

CannaVest was a leading exhibitor of the 35th annual Natural Products Expo West, on March 4-8, 2015 at the Anaheim Convention Center in California. The event brought together a community of more than 71,000 industry members and over 2,700 exhibiting companies. CannaVest sponsored a standing room only non-branded educational lecture on the Nutritional and Medical Applications for Cannabidiol (CBD). The Natural Products Expo West is the world's largest natural, organic, and healthy products event.

CannaVest Corp. (CANV), closed Thursday's trading session at $1.55, down 6.06%, on 93,312 volume with 115 trades. The average volume for the last 60 days is 59,122 and the stock's 52-week low/high is $1.50/$21.25.

Catasys, Inc. (CATS)

PennyStocks24, OTCBB Journal, StocksImpossible, First Penny Picks, Stock Commander, Penny Stock Prophet, Planet Penny Stocks, Buzz Stocks, Penny Pick Finders, and Stock Onion reported this week on Catasys, Inc. (CATS), and we choose to highlight the Company also, here at the QualityStocks Daily Newsletter.

Catasys, Inc. is a provider of proprietary health management services to health insurers and employers. The OTCQB-listed Company provides specialized health management services via a network of licensed and company managed health care providers. Catasys established to serve health care payors, and it provides unique and integrated substance dependence treatment solutions for its members. Catasys has its corporate headquarters in Los Angeles, California.

The Catasys substance dependence program improves member health, thus lowering overall costs. The proprietary program addresses substance dependence as a chronic disease. The program centers on the whole health of the member. The program delivers integrated medical and psychosocial interventions in combination with long-term care coaching.
The design of Catasys’ OnTrak program is to improve member health and simultaneously lower costs to the insurer through employing patient centric treatment, which integrates evidence based medical and psychosocial interventions along with care coaching in a 52-week outpatient program. 

Catasys provides its proprietary OnTrak integrated substance dependence solutions for third-party payors in Florida, Kansas, Kentucky, Louisiana, Massachusetts, New Jersey, Oklahoma, West Virginia and Wisconsin. The Company has recently contracted to expand to Illinois. OnTrak is improving member health and, simultaneously, is demonstrating reduced inpatient and emergency department utilization driving a more than 50 percent reduction in total health care costs for enrolled members.

This week, Catasys announced that it has started enrolling members with anxiety disorder in its OnTrak Program with a top national health care provider in Kansas. This past March, Catasys announced the agreement to add members with anxiety to its existing OnTrak program in Kansas, considerably increasing the number of eligible lives in Kansas' population.

In April, Catasys announced a multi-year agreement with Health Alliance Medical Plans (HAMP) to offer its OnTrak Program to eligible HAMP members in Illinois, therefore adding roughly 100,000 Commercially Equivalent Lives (CELs) covered under its OnTrak Program.

Catasys, Inc. (CATS), closed Thursday's trading session at $1.60, down 9.09%, on 25,505 volume with 66 trades. The average volume for the last 60 days is 12,925 and the stock's 52-week low/high is $1.04/$2.45.

HII Technologies, Inc. (HIIT)

Pumps and Dumps, StocksImpossible, OTCBB Journal, StockProfessors, LuckyStockPicks, Gold Stock News, PennyStockShark, PennyStockRewards.com, and USA Market News reported earlier on HII Technologies, Inc. (HIIT), and we report on the Company today, here at the QualityStocks Daily Newsletter.

HII Technologies, Inc. is an oilfield service company focused in frac water management, oilfield power, and safety services. It has operations in Texas, Oklahoma, Ohio and West Virginia. The Company’s frac water management division does business as AES Water Solutions, Hamilton and AquaTex. Its onsite oilfield contract safety consultancy does business as AES Safety Services. Its mobile oilfield power subsidiary does business as Sage Power Solutions, Inc. (formerly South Texas Power (STP)). Most of HII Technologies’ activity is in Texas and Oklahoma. Founded in 1997, the Company is headquartered in Houston, Texas.

HII Technologies centers on the critical service areas of Water, Safety and Power. It is positioned to take advantage of the significant anticipated growth in horizontal drilling and hydraulic fracturing within the U.S.’s active shale and unconventional "tight oil" plays. The holding company, HII Technologies' objective is to bring proven technologies to its operating divisions to build a long-term competitive advantage for the Company’s stakeholders.

AES Water Solutions provides services in transporting high volumes of water by way of 10 inch aluminum pipe from the source to the drill site. The piping is mobile; it can be installed quickly at any location.

AquaTex offers a holistic water management approach to handling oil field frac water operations. It offers water transfer and treatment services. These include oilfield water transfer equipment; high volume water transfer equipment; frac water pit design construction & management, and also frac water treatment equipment.

HII Technologies’ SAFETY division, through its operating subsidiary AES Safety Services, offers Safety Engineers on a contract basis to exploration and production companies. These Safety Engineers normally work customized shifts to the energy company’s criteria.

In February, HII Technologies announced that it renamed its Power division subsidiary known as KMHVC, Inc. dba South Texas Power (STP) to Sage Power Solutions, Inc. This is part of a rebranding initiative for its Power division.

This week, HII Technologies announced a $3.05 Million private placement with institutional and accredited investors. ROTH Capital Partners acted as the only placement agent for the offering.

HII Technologies, Inc. (HIIT), closed Thursday's trading session at $0.3049, up 1.60%, on 73,611 volume with 45 trades. The average volume for the last 60 days is 65,146 and the stock's 52-week low/high is $0.3001/$1.14.

Elite Pharmaceuticals, Inc. (ELTP)

Top Stock Picks, Stock Analyzer, PennyStocks24, and Pumps and Dumps reported earlier on Elite Pharmaceuticals, Inc. (ELTP), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Elite Pharmaceuticals, Inc. develops oral sustained and controlled release products.  Additionally, it provides contract manufacturing for Ascend Laboratories (a subsidiary of Alkem Laboratories Ltd.). Furthermore, the Company has partnered with Epic Pharma (a private pharmaceutical company in Laurelton, New York) for the manufacturing and distribution of 11 approved products pending manufacturing site, with Hi-Tech Pharmacal to develop an intermediate for a generic product, and a Hong Kong based company to develop a branded product for the U.S. market and its territories.

Elite Pharmaceuticals operates a GMP and DEA registered facility for research, development, and manufacturing located in Northvale, New Jersey, its corporate headquarters. Elite owns generic and OTC products licensed to TAGI Pharma, Epic Pharma, and Valeant Pharmaceuticals International, with seven commercial products now selling, additional approved products pending manufacturing site transfer, and a product under review pending approval by the Food and Drug Administration (FDA).

The Company’s lead pipeline products include abuse resistant opioids using its patented proprietary technology, and a once-daily opioid. They are sustained release oral formulations of opioids for the treatment of chronic pain, which address two of the limitations of existing oral opioids: the provision of consistent relief of baseline pain levels and deterrence of potential abuse.

Elite announced in July 2014 the first dosing of a pivotal bioequivalence (BE) study in healthy volunteers for ELI-201. This is its twice daily abuse deterrent oxycodone/naltrexone product, using Elite's proprietary pharmacological abuse deterrent technology. The study is an open-label, single-dose, partially-randomized crossover study in healthy adult subjects.

Elite Pharmaceuticals announced this past December successful results from the pivotal BE study for ELI-201. The study demonstrated the Company’s product is bioequivalent to the branded drug based on pharmacokinetic measures. Final findings of bioequivalence are dependent upon FDA review.

Elite Pharmaceuticals announced this past February guidance concerning its Phase III trial for ELI-200, which is an abuse deterrent opioid product. It has submitted a study protocol to the FDA. The expectation is that dosing for the study will begin soon after the FDA comments on the protocol are received by Elite Pharmaceuticals.

The Phase III study will enroll approximately 150 patients. The study is a multi-center, randomized, multiple-dose, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of abuse deterrent ELI-200 for the treatment of adults with moderate to severe pain following surgery.

In April, Elite Pharmaceuticals announced the launch of generic Hydroxyzine HCI 10 mg, 25 mg, and 50 mg tablets through Epic Pharma. Hydroxyzine is indicated for symptomatic relief of anxiety and tension associated with certain disease states and management of pruritus because of certain allergic conditions. Epic will manufacture, package, as well as distribute the product under the Manufacturing and License Agreement earlier signed between Epic and Elite Pharmaceuticals.

Elite Pharmaceuticals, Inc. (ELTP), closed Thursday's trading session at $0.2111, up 2.43%, on 634,426 volume with 100 trades. The average volume for the last 60 days is 1,183,295 and the stock's 52-week low/high is $0.1745/$0.47.

MabVax Therapeutics Holdings, Inc. (MBVX)

PennyStockRumors.net and TopPennyStockMovers reported recently on MabVax Therapeutics Holdings, Inc. (MBVX), and we are highlighting the Company as well, here at the QualityStocks Daily Newsletter.

A clinical stage oncology drug development company, MabVax Therapeutics Holdings, Inc. is a cancer diagnostic and Immunotherapy Company. It focuses on the development of vaccine and antibody based therapies to address unmet medical needs in the treatment of cancer. Its lead antibody candidate HuMab 5B1 is undergoing development as both a diagnostic product and therapeutic agent for the diagnosis and treatment of GI cancers and specifically pancreatic cancer. MabVax Therapeutics Holdings is based in San Diego, California.

The Company has discovered a pipeline of human monoclonal antibody products based on the protective immune responses generated by patients who have been immunized against targeted cancers with MabVax’s proprietary vaccines. The HuMab 5B1 antibody product is scheduled to enter Phase I clinical trials later in 2015. The Company generates its pipeline of antibody based product candidates from patients who have been vaccinated with the proprietary vaccines MabVax has licensed from Memorial Sloan-Kettering Cancer Center (MSKCC).

The Company’s therapeutic vaccines were developed at MSKCC and exclusively licensed to MabVax. The vaccines are administered in the adjuvant setting and provoke a protective antibody response. The antibodies search out circulating tumor cells and micrometastases to kill them before they can cause cancer recurrence.

MabVax Therapeutics has the exclusive license to a portfolio of therapeutic vaccines from MSKCC. It has two cancer vaccines targeting recurrent sarcoma and ovarian cancer in proof of concept Phase II multi-center clinical trials. MabVax’s plan is to have a third vaccine targeting neuroblastoma ready for Phase II clinical development later in 2015.

Last week, MabVax Therapeutics announced that it received the final report on toxicology testing of its HuMab 5B1 antibody that was completed by a top independent contract research organization.  The report detailed that the antibody, given in either a single dose or repeated doses, had no significant adverse findings even at the highest dosage levels tested. MabVax said that these results further validate its decision to advance HuMab 5B1 into Phase 1 clinical trials before the end of this year.

MabVax Therapeutics Holdings, Inc. (MBVX), closed Thursday's trading session at $2.47, down 1.98%, on 85,441 volume with 120 trades. The average volume for the last 60 days is 120,467 and the stock's 52-week low/high is $0.832/$15.00.

GroGenesis, Inc. (GROG)

Flagler Financial Group, Investopedia, SECFilings.com News, VectorVest, Insider Wealth Alert, Wyatt Investment Research, and Investors Alley reported recently on GroGenesis, Inc. (GROG), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

GroGenesis, Inc.’s goal is to become a foremost producer of natural plant growth health technologies. The Company is rights holders, developers, and manufacturers of innovative plant health enhancement products branded as AgraBurst and AgraBlast. GroGenesis is working to position the Company in the fast expanding fertilizer, surfactant, fungicide, and plant growth enhancement space as a business distinguished for safe, productive technology and proprietary solutions. GroGenesis has its headquarters in Springville, Tennessee.

Its AgraBurst is a plant growth technology blended from processed extracts of natural plant materials, which directly improves the positive effects of commercial fertilizers and available nutrients. AgraBurst™ is its flagship product. It works at the cellular level to speed up the absorption of vital nutrients, chemicals, and water by way of molecular penetration of the plant’s leaf.

In addition, GroGenesis offers "AgraBlast" an eco-friendly, non-toxic alternative to synthetic fungicides. When used in combination (as directed), GroGenesis provides a unique solution for the control of plant pathogenic fungi and for plant remediation and stimulation of yields. AgraBlast is a broad-spectrum algaecide, fungicide, bactericide, and general sanitation product for the control and prevention of horticultural diseases and pathogens in pre-harvest, post-harvest and storage of field-grown crops.

GroGenesis is also working to become a world leading provider of eco-friendly, non-toxic, plant growth and health enhancers. Furthermore, the Company is working to enable farmers and agribusinesses to substantially boost crop yields globally while mitigating the effects of over-fertilization. It offers a technology that alleviates many of the challenges of fertilizer application through introducing a surfactant to plant foliage as a unique delivery system to hasten absorption of water and nutrients on-leaf, while at the same time increasing root uptake.

Yesterday, GroGenesis announced that it received approval from OTC Markets Group to upgrade to the OTCQB venture stage marketplace. GroGenesis was advised the transition from the OTC Pink open marketplace to the OTCQB is effective May 13, 2015.

GroGenesis, Inc. (GROG), closed Thursday's trading session at $0.4085, up 7.50%, on 43,025 volume with 31 trades. The average volume for the last 60 days is 77,476 and the stock's 52-week low/high is $0.3412/$1.06.


The QualityStocks
Company Corner


IFAN Financial, Inc. (IFAN)

The QualityStocks Daily Newsletter would like to spotlight IFAN Financial, Inc. (IFAN). Today, IFAN Financial, Inc. closed trading at $0.12, up 18.81%, on 254,885 volume with 52 trades. The stock’s average daily volume over the past 60 days is 44,299, and its 52-week low/high is $0.0114/$1.01.

IFAN Financial, Inc. today announced it has been selected by digital branding agency Blue Like Neon to provide it with cutting-edge mobile payments solutions. Blue Like Neon utilizes a multi-pronged, market enhancement strategy to create campaigns that allow clients to better engage with their customers. These campaigns are also designed to increase visibility and retention. IFAN Financial's mobile gateway will enhance this approach by providing Blue Like Neon with a social commerce platform that may be customized for each client's unique needs.

IFAN Financial, Inc. (IFAN) and its wholly owned subsidiaries, iPIN Technologies and Mobicash America, are engaged in the design, development and distribution of software that enhances and enables mobile payments. The San Diego-based company has a growing portfolio of solutions, including the ability to use a debit card and corresponding PIN number while purchasing online via mobile phone, tablet, or computer and peer-to-peer cash transfers.

Keeping pace with the evolution of the information and communication (ICT) market, iPIN Technologies intends to provide a range of processing services for the industry’s future devices. The company is currently developing a new method of online selling through debit card payments and processing. iPIN technology attaches to any smartphone through the headphone jack and converts the device into a consumer PIN debit, same-as-cash payment solution. Using the iPIN Debit app, transactions are processed through the private and secure iPIN Technologies Network.

Mobicash America is an early-stage technology company that develops mobile payment solutions. The company’s platform product, Quidme, utilizes the text messaging function of a mobile phone, allowing the technology to operate on almost any phone or network, with or without data service. The functionality of the Quidme platform allows users to pay bills, purchase goods and services, and to send money to friends and relatives located locally or internationally via simple text message.

IFAN Financial continues to explore opportunities to expand its product portfolio to meet the growing demands for consumer/merchant convenience, speed and security within the mobile commerce market. Products in development will combine the functionality of social media, e-commerce and banking with the broader conveniences of the mobile environment. Disclaimer

IFAN Financial, Inc. Company Blog

IFAN Financial, Inc. News:

IFAN Financial Payment Gateway Adopted by Digital Branding Agency Blue Like Neon to Bolster Customers' eCommerce Capabilities

IFAN Financial, Inc. (IFAN) Expands Board of Directors With Addition of Technology Venture Veteran

IFAN Financial Applauds Facebook's Move Into the Mobile Payments Industry, Foresees Ancillary Opportunities

Well Power Inc. (WPWR)

The QualityStocks Daily Newsletter would like to spotlight Well Power Inc. (WPWR). Today, Well Power Inc. closed trading at $0.0016, up 23.08%, on 11,807,000 volume with 48 trades. The stock’s average daily volume over the past 60 days is 2,711,725, and its 52-week low/high is $0.0013/$0.2789.

Well Power Inc. (WPWR) has secured the licensing rights to Texas with the first right of refusal on the other US states to a new technology solution to process waste natural gas, such as vented, flared or stranded gas, into “clean power” and engineered fuels, including no-sulphur diesel and diluents. Based on proprietary technology, this solution is mobile, high-yield and can be deployed with minimum capital expenditure.

The company plans to be able to provide its technology with full-service engineering, design, construction, modular fabrication, maintenance and construction management services to clients in the upstream areas of exploration and production. Well Power will also offer consulting services, process assessments, facility appraisals, feasibility studies, technology evaluations, project finance structuring and support, and multi-client subscription services.

Approximately 2.4 million barrels of oil equivalent is wasted each day by gas flaring alone, resulting in $10 billion of lost revenue and 400 million metric tons of CO2 equivalent global greenhouse gas emissions each year. Additionally, environmental degradation associated with gas flaring has been shown to have a significant impact on local populations, often resulting in loss of livelihood and severe health issues.

Well Power’s Micro Refinery Unit (MRU) offers the opportunity to create value from a wasted resource while simultaneously enabling wider access to energy, improved environmental conditions, and economic development for local populations. By eliminating legacy flaring and minimizing new flaring, the company is well positioned to take a leadership role in the ongoing push for sustainable resource development and energy efficiency. Disclaimer

Well Power Inc. Company Blog

Well Power Inc. News:

Well Power Inc. Appoints Professional Engineer, Oil & Gas Veteran to Board of Directors

Well Power - Letter from President to Shareholders

Well Power Inc. to host second webinar on proprietory micro-refinery technology

Save The World Air, Inc. (ZERO)

The QualityStocks Daily Newsletter would like to spotlight Save The World Air, Inc. (ZERO). Today, Save The World Air, Inc. closed trading at $0.40, up 5.26%, on 72,425 volume with 31 trades. The stock’s average daily volume over the past 60 days is 114,652, and its 52-week low/high is $0.3401/$0.839.

Save The World Air, Inc. (ZERO) (“STWA”) provides the global energy industry with patent-protected industrial equipment designed to deliver measurable performance improvements to crude oil pipelines. Developed in partnership with leading crude oil production and transportation entities, STWA’s high-value solutions address the enormous capacity inadequacies of domestic and overseas pipeline infrastructures that were designed and constructed prior to the current worldwide surge in oil production.

In support of our clients’ commitment to the responsible sourcing of energy and environmental stewardship, STWA combines scientific research with inventive problem solving to provide energy efficiency ‘clean tech’ solutions to bring new efficiencies and lower operational costs to the upstream, midstream and gathering sectors. STWA’s flagship product, AOT (Applied Oil Technology) improves the economics of transporting crude oil by reducing the viscosity of oil in pipelines. Once deployed on pipeline pumping stations, production and transportation companies benefit from the safer, more cost-effective delivery of greater volumes of oil while reducing energy consumption at pumping stations and lowering CO2 emissions.

The AOT technology is the result of years of research conducted at Temple University (Philadelphia, Penn.) and is the world’s first ASME-certified industrial hardware to use the principles of electrorheology, the study of applying non-uniform electrical fields to change the mechanical behavior of fluids, to significantly reduce the viscosity of crude oil within pipelines during maximum flow conditions. Field tested by the U.S. Department of Energy, independent testing laboratories such as ATS RheoSystems and fabricated to exacting industry standards by STWA’s supply chain partners, the efficacy of AOT to increase flow rates, prevent bottlenecks, reduce pump station power consumption, enhance pipeline integrity and optimize flow assurance has been proven repeatedly in the lab and on a 300,000 barrel per day pipeline.

STWA is also commercializing STWA Joule Heat, an energy-efficient technology for heating crude oil in pipelines to improve flow. Unlike traditional trace heating systems which generate heat via a resistive trace heating element which transfers energy into the oil, the STWA solution applies an electrical field directly to oil, generating heat within the flow itself. The result is optimal heat conductivity and performance with less power and in a smaller form factor.

Guided by a dynamic management team led by Greggory Bigger, Chief Executive Officer, Chairman and a strong independent board of directors of energy industry veterans, STWA is a revenue generating company with a solid cash position, clean balance sheet and a proven ability to develop and deliver industrial-grade equipment that support the company’s mission and enhance shareholder value. As the exclusive licensee of oil viscosity reduction processes developed at Temple University and owner of 48 worldwide patents related to the use of electricity to change the mechanical behavior of oil and liquid natural gas, STWA is well-positioned to capitalize on the explosive growth opportunities in the global crude oil production and transportation sector. More information is available at: www.stwa.com. Disclaimer

Save The World Air, Inc. Company Blog

Save The World Air, Inc. News:

STWA Reports 2015 First Quarter Financial Results

STWA Issues Letter to Shareholders

STWA Selected as a Finalist for the 2015 Global Petroleum Show Awards

Sibling Group Holdings, Inc. (SIBE)

The QualityStocks Daily Newsletter would like to spotlight Sibling Group Holdings, Inc. (SIBE). Today, Sibling Group Holdings, Inc. closed trading at $0.0601, up 5.25%, on 12,000 volume with 2 trades. The stock’s average daily volume over the past 60 days is 80,752, and its 52-week low/high is $0.0423/$0.22.

Sibling Group Holdings, Inc. (SIBE) is enhancing and delivering 21st century learning with advanced technology and education management operations. Accessing funds from the public capital markets is part of the company’s unified strategy to accelerate the improvement of Pre-K, K-12 and post-secondary education around the world. Better educated children and adults, sustainable and cost effective instructional models, and reduced dependence on governmental funding are the end results.

Existing offerings include professional development for the teaching profession; educational technology, including classroom management tools; a comprehensive and flexible online curriculum; an aggregation platform for massive open online courses, and academic and skills credentialing. Investments are being made in specialized curriculum such as STEM (science, technology, engineering and math), ESL (english as a second language), SEL (social and emotional learning), and Special Ed aimed at supporting students with special needs and their teachers.

Sibling Group is acquiring various Ed-tech businesses and components with the goal of building the first complete solution for the delivery and management of educational content, and tracking educational results, in the digital media – from curriculum to course certification. The recent acquisition of Blended Schools Network (BSN), which serves over 160 school districts with 300,000 course enrollments and currently offers 212 different online courses, is a great example and has provided Sibling Group with extensive infrastructure and solid groundwork for growth in a rapidly growing industry.

IBIS Capital is forecasting fifteen-fold growth in the e-learning market over the next 10 years and has even suggested that under certain circumstances the transition to digital education may be quicker and more disruptive than ever observed in the media industry. With a strong, highly experienced management team, Sibling Group is in a unique position to continue expanding its portfolio through additional acquisitions and fundamental growth. Disclaimer

Sibling Group Holdings, Inc. Company Blog

Sibling Group Holdings, Inc. News:

Sibling Groups Blended Schools Network Powers Mountain House High Schools Personalized Learning; BSN Curriculum Achieves California A-G Certification

Sibling Group's Urban Planet Mobile Deepens Strategic Partnership With Imagine Easy Solutions and EasyBib; UPMs Writing Planet Essay Scoring Solution to Be Offered Across All Imagine Easy Citation Websites Worldwide

Strategic Partner Shenzhen Times Increases Stake in Sibling Group; $5,500,000 Warrant Exercise to Fund Growth Initiatives

Mobile Lads Corp. (MOBO)

The QualityStocks Daily Newsletter would like to spotlight Mobile Lads Corp. (MOBO). Today, Mobile Lads Corp. closed trading at $0.0649, up 4.68%, on 152,800 volume with 29 trades. The stock’s average daily volume over the past 60 days is 39,624, and its 52-week low/high is $0.05/$0.42.

Mobile Lads Corp. (MOBO) designs and delivers secure, wide-area wireless transaction software solutions for the consumer finance, web and health payment processing sectors. The company’s solutions provide streamlined, continuous access to time-sensitive information and data on multiple network standards. Mobile Lads’ products and services, offered through its Xtreme Mobility division, centers on three core technologies that simplify and secure wireless communications: xmVerify, xmBilling, and xmOne.

xmVerify is a real-time mobile transaction security service that prevents credit card fraud by giving users control over the authorization process when making purchases. Using one of the best cryptographic services, and in compliance with most all available platforms, xmVerify sends a transaction authorization request directly to the user’s mobile phone to ensure authenticity.

xmBilling is a mobile platform that provides customers with a convenient and secure way to review and authorize automatic billing transactions, easing the challenges of automated and volume-based billing. The system sends the user a text message with a URL leading to an online e-bill where they can review details of the bill and authorize the payment via credit card with the use of their PIN number.

The xmOne mobile platform provides an array of encrypted mobile services, including top-up, payment processing, emergency notification and marketing, ideal for students and higher education facilities. xmOne interfaces with a school’s existing campus card account system to enable students to perform a variety of banking transactions from their cell phones. The university or college benefits from increased usage of the flex-dollar ecosystem, reduces overhead from ADMs, and can be customized to each school’s individual brand.

Mobile Lads is guided by a management team with a unique blend of in-depth technical expertise in wireless channel communications and a solid background in business strategy and consumer analysis. The company’s vision is to grow as a leading-edge wireless solution provider by enabling innovative, wide-area communication solutions on a global scale. Disclaimer

Mobile Lads Corp. Company Blog

Mobile Lads Corp. News:

Mobile Lads Begins Operating And Buys Control Of North American Shopping Network Simbadeals.com From DoMark International

Mobile Lads Begins Operating North American Shopping Network Simbadeals.com

Mobile Lads Purchases Majority of North American Shopping Network From Domark International

Consorteum Holdings, Inc. (CSRH)

The QualityStocks Daily Newsletter would like to spotlight Consorteum Holdings, Inc. (CSRH). Today, Consorteum Holdings, Inc. closed trading at $0.0064, off by 1.54%, on 76,886 volume with 2 trades. The stock’s average daily volume over the past 60 days is 112,759, and its 52-week low/high is $0.0013/$0.018.

Consorteum Holdings, Inc. (CSRH) has spent the last 3 years developing relationships and licensing agreements to take the center stage in the emerging market of mobile gaming. The company has the capability to deliver rich mobile content to end users who will use their smart phones in ways that could not even have been imagined five years ago.

Specializing in delivery of mobile content, mobile payment solutions and products through a mix of on-deck partnerships, license agreements, and joint venture revenue share arrangements, the company operates as a technology and services aggregator to meet the diverse needs of its client base. This approach enables unparalleled flexibility when sourcing solutions, resulting in smarter, faster deployment of technologies, competitive pricing, and potential for new streams of revenue.

ThreeFiftyNine Inc., a wholly owned subsidiary, hired a software development team that had previously designed the world’s first regulatory compliant mobile platform for delivery of gaming content created by a third party. The platform, which has met the rigorous standards of the Nevada Gaming Board, the gold standard in regulatory gaming, represents the first generation software delivery platform for mobile devices. The development team spent the past 5 years and millions of dollars in non-recurring engineering costs to complete the development of the platform. At the heart is the capability to deliver any digital content across any cellular network to any mobile device. This key differentiator makes it possible for Consorteum to approach many different markets that are in the business of providing mobile connectivity and mobile content.

Consorteum’s mobile initiatives will benefit multiple business verticals. The company has strategically designed its business initiatives to create repetitive transactions on an ongoing basis. Consorteum's goal is to have their customers think of them more as partners, rather than just technology providers, for longer-lasting, more profitable relationships. Disclaimer

Consorteum Holdings, Inc. Company Blog

Consorteum Holdings, Inc. News:

Consorteum Holdings Signs License Agreement With NYG Holdings

Consorteum Holdings Signs Mobile Application Development Contract With Bet Butler Limited

Consorteum Holdings Launches New Mobile Results App for Popular Keno Game

VistaGen Therapeutics, Inc. (VSTA)

The QualityStocks Daily Newsletter would like to spotlight VistaGen Therapeutics, Inc. (VSTA). Today, VistaGen Therapeutics, Inc. closed trading at $10.00, even for the day. The stock’s average daily volume over the past 60 days is 211, and its 52-week low/high is $3.16/$15.00.

VistaGen Therapeutics, Inc. (VSTA) is a biotechnology company applying stem cell technology for drug rescue and cell therapy. Drug rescue combines human stem cell technology with modern medicinal chemistry to generate new chemical variants ("drug rescue variants") of once-promising drug candidates that have been discontinued during late-stage preclinical development due to heart or liver safety concerns. VistaGen also focuses on cell therapy, or regenerative medicine, which includes repairing, replacing or restoring damaged tissues or organs

VistaGen's versatile stem cell technology platform, Human Clinical Trials in a Test Tube™, has been developed to provide clinically relevant predictions of potential heart and liver toxicity of promising new drug candidates long before they are ever tested on humans.

By more closely approximating human biology than conventional animal studies and other nonclinical techniques and technologies currently used in drug development, VistaGen's human stem cell-based bioassay systems can improve the predictability of the drug development cycle and lower the cost of new drug research and development by identifying product failures earlier in the cost curve. According to the Food and Drug Administration even only a ten percent improvement in predicting failure before clinical trials could save $100 million in development costs, which savings ultimately could be passed on to patients.

Using mature human heart cells produced from stem cells, VistaGen has developed and internally validated CardioSafe 3D™, a novel three-dimensional (3D) bioassay system for predicting the in vivo cardiac effects of new drug candidates before they are tested in humans. VistaGen is now focused on using CardioSafe 3D™ to generate up to two new, safer small molecule drug rescue variants every twelve to eighteen months. VistaGen anticipates that these drug rescue variants will be modified versions of once-promising new drug candidates that have been discontinued by pharmaceutical companies and academic research institutions because of heart toxicity concerns, despite substantial prior investment and positive efficacy data demonstrating their potential therapeutic and commercial benefits. In most cases, VistaGen plans to license or sell its new, safer drug rescue variants in strategic partnering arrangements with global pharmaceutical companies, arrangements providing VistaGen with both near term and downstream milestone payments and economic participation rights but without future development cost obligations.

AV-101, VistaGen's lead small molecule prodrug candidate, has successfully completed Phase I clinical development in the U.S. for treatment of neuropathic pain, a serious and chronic condition affecting millions of people worldwide, depression, and other neurological diseases and conditions. To date, the U.S. National Institutes of Health (NIH) has awarded VistaGen over $8.75 million for development of AV-101. Management anticipates strategically out-licensing AV-101 to a development and marketing partner in 2013.

VistaGen is also developing LiverSafe 3D™, a novel predictive liver toxicity and drug metabolism bioassay system for drug rescue applications. In parallel with drug rescue activities, the Company is funding early-stage nonclinical studies focused on potential cell therapy applications of its Human Clinical Trials in a Test Tube™ platform. Disclaimer

VistaGen Therapeutics, Inc. Company Blog

VistaGen Therapeutics, Inc. News:

VistaGen and NIH Sign Agreement for NIH-Sponsored Phase 2 Study of Orally-Active AV-101 in Major Depressive Disorder

Dr. Gerard Sanacora Joins VistaGen's Clinical and Scientific Advisory Board

VistaGen Signs Letter of Intent With National Institute of Mental Health for NIH-Sponsored Phase 2 Clinical Study of AV-101 in Major Depressive Disorder


Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters





Juicy Penny Stocks



By The Numbers Charts

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors


The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.


About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251